Top Story Today
Denali Cracks the Blood-Brain Barrier With a Molecular Disguise
For 20 years, Hunter syndrome patients had a treatment that helped their bodies but left their brains untouched. That era just ended. The FDA granted accelerated approval to Denali's Avlayah (tividenofusp alfa), making it the first enzyme replacement therapy engineered to cross the blood-brain barrier. The trick: Denali fused its enzyme to a molecular tag that hijacks the brain's iron-delivery system, essentially disguising the drug as a routine shipment. In trials, 93% of pediatric patients saw brain biomarkers drop to normal range within 24 weeks.
Why it matters: The real prize isn't just one rare disease; it's Denali's Transport Vehicle platform, which could unlock brain-penetrant therapies for Sanfilippo syndrome, Pompe disease, and beyond. If the approach works broadly, it cracks open a problem that's stumped drug developers for decades.
Read more →Regulatory Shakeup
The FDA Wants One Trial Instead of Two. Wall Street Has Questions.
FDA Commissioner Marty Makary is flipping the burden of proof: one pivotal trial plus supporting evidence is now the default, and reviewers must justify demanding a second. Add AI-powered filing reviews, a new pathway for ultra-rare diseases, and biosimilar reforms that could save companies approximately $20 million per PK study. The catch? Early execution has been rocky, with rejected priority voucher applications and unpredictable public comments spooking investors.
Read more →Science & Discovery
MIT Open-Sourced a Drug-Screening AI That Matches the Gold Standard
MIT and Recursion released Boltz-2, an open-source AI model that predicts drug binding affinity as accurately as the industry's gold-standard physics method, but 1,000 times faster (about 20 seconds per prediction on a GPU). Fully open under an MIT license, it's a direct shot at DeepMind's restricted AlphaFold3. For small biotechs and academic labs priced out of enterprise-level screening tools, the playing field just got considerably more level.
Read more →Talent Wars
GSK Raided Sanofi for a 25-Year Vaccine Veteran
GSK hired Sanjay Gurunathan, who spent a quarter century at Sanofi accumulating 20-plus regulatory approvals and eight major Phase 3 trials, as its new global head of vaccine R&D. The timing is no accident: Moderna's mRNA RSV vaccine now competes directly with GSK's Arexvy, and 73 combined mRNA programs from Moderna and Pfizer/BioNTech are redrawing the competitive map. GSK is playing offense.
Read more →